Jarrett P, Camargo CA, Jr., Coomarasamy C, Scragg R
Inclusion Criteria Exclusion Criteria Timeline for a Trial Participant Screening Participants are screened for eligibility to participate in the trial Treatment Participants receive weekly subcutaneous injections of either CagriSema or Tirzepatide, with a dose escalation period followed by maintenance dosing Follow-up Participants are monitored for safety and effectiveness after treatment What Are the Treatments Tested in This Trial
Continue as a Guest Directions Of Use Dosage & Administration: Give dose by subcutaneous injection only
Metabolic pathway research, adipocyte behavior studies, mitochondrial efficiency analysis, and NAD+-related biochemical investigations
If you are currently on compounded semaglutide , the same principles of combination with AOD 9604 apply, just with somewhat lower expected results from the GLP-1 component
It comes as Peptide lyophilized powder, which is dry and easy to store